Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.014
Sell
RSI(14)
26.469
Sell
STOCH(KDJ)(9,3,3)
36.739
Neutral
ATR(14)
0.049
High Vlolatility
CCI(14)
-172.849
Sell
Williams %R
73.333
Sell
TRIX(12,20)
-0.579
Sell
StochRSI(14)
0.000
Oversold
Search
Cocrystal Pharma Inc
COCPAdd to Watchlist
0.820USD
-0.048-5.50%
Close 07-31 16:00（ET）Quotes delayed by 15 min
11.31MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-5.50%
5 Days
-8.90%
1 Month
-21.90%
6 Months
-16.34%
Year to Date
-16.24%
1 Year
-52.60%
Key Figures
0.880Open
0.880High
34.92KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.25%Turnover Ratio
0.868Prev. Close
0.820Low
19.74KTurnover
LossP/E Static
2.75P/B
0.00%Div Yield TTM
-97.64%ROA
2.67052wk High
0.98Volume Ratio
-17.50MNet Profit
13.79MShares
-0.7228EPS TTM
1.44Beta
-154.62%ROE
0.85952wk Low
6.91%Amplitude
100.00%Gross Margin
11.31MMarket Cap
-3.77Reward/Risk
4.40%Risk Rate
TradingKey Stock Score of Cocrystal Pharma Inc
Currency: USD Updated: 2026-07-31Key Insights
Cocrystal Pharma Inc's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 141 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 9.00.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Cocrystal Pharma Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Cocrystal Pharma Inc Highlights
StrengthsRisks
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses (HCV). It is developing small molecule antiviral therapeutics that inhibit the essential viral replication function of RNA viruses, causing acute and chronic viral diseases. It has several candidates under development for the treatment of influenza infection. CC-42344 is a novel PB2 inhibitor, which is a preclinical lead for the treatment of pandemic and seasonal influenza A. It also develops broad-spectrum influenza antivirals targeting replication enzymes of influenza A and B strains. Its broad-spectrum antiviral drug candidate, CDI-988, is an oral treatment for SARS-CoV-2, the virus that causes COVID-19. Its CC-31244, an HCV NNI, is a pan-genotypic inhibitor of NS5B polymerase for the treatment of HCV.
Fairly Valued
The company’s latest PE is -1.13, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 769.42K shares, decreasing 3.50% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
9.000
Target Price
+934.13%
Upside Space
Cocrystal Pharma Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
1
analysts
Buy
Current Rating
9.000
Target Price
+934.13%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Cocrystal Pharma Inc
COCP
1
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Ionis Pharmaceuticals Inc
IONS
25
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
0.882
Sell
MA10
0.903
Sell
MA20
0.943
Sell
MA50
1.004
Sell
MA100
1.141
Sell
MA200
1.085
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Cocrystal Pharma Inc Info
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses (HCV). It is developing small molecule antiviral therapeutics that inhibit the essential viral replication function of RNA viruses, causing acute and chronic viral diseases. It has several candidates under development for the treatment of influenza infection. CC-42344 is a novel PB2 inhibitor, which is a preclinical lead for the treatment of pandemic and seasonal influenza A. It also develops broad-spectrum influenza antivirals targeting replication enzymes of influenza A and B strains. Its broad-spectrum antiviral drug candidate, CDI-988, is an oral treatment for SARS-CoV-2, the virus that causes COVID-19. Its CC-31244, an HCV NNI, is a pan-genotypic inhibitor of NS5B polymerase for the treatment of HCV.
Ticker SymbolCOCP
CompanyCocrystal Pharma Inc
CEOMartin (James J)
Websitehttps://www.cocrystalpharma.com/
Shareholders
Related Instruments
-0.53%
+0.23%
-1.00%
-2.54%
+0.33%
-1.44%
-0.61%
-0.79%
-8.78%
+0.48%
+0.70%
-1.00%
-0.69%
+0.49%
-1.08%
+3.32%
0.00%
+1.34%
-0.87%
-2.17%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.640
-24.790 (-7.43%)
200.760
+5.720 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of Cocrystal Pharma Inc (COCP)?
The current price of Cocrystal Pharma Inc (COCP) is 0.82.
What is the symbol of Cocrystal Pharma Inc?
The ticker symbol of Cocrystal Pharma Inc is COCP.
What is the 52-week high of Cocrystal Pharma Inc?
The 52-week high of Cocrystal Pharma Inc is 2.67.
What is the 52-week low of Cocrystal Pharma Inc?
The 52-week low of Cocrystal Pharma Inc is 0.86.
What is the market capitalization of Cocrystal Pharma Inc?
The market capitalization of Cocrystal Pharma Inc is 11.31M.
Is Cocrystal Pharma Inc (COCP) currently rated as Buy, Hold, or Sell?
According to analysts, Cocrystal Pharma Inc (COCP) has an overall rating of Buy, with a price target of 9.00.
What is the Earnings Per Share (EPS TTM) of Cocrystal Pharma Inc (COCP)?
The Earnings Per Share (EPS TTM) of Cocrystal Pharma Inc (COCP) is -0.78.